Determination of a comprehensive alternative splicing regulatory network and combinatorial regulation by key factors during the epithelial-to-mesenchymal transition

Molecular and Cellular Biology

Volumn 36, Issue 11, 2016, Pages 1704-1719

  Yang, Yueqin ^a,b   Park, Juw Won ^c,d,e   Bebee, Thomas W ^a,b   Warzecha, Claude C ^a,b,g   Guo, Yang ^c,f   Shang, Xuequn ^f   Xing, Yi ^c   Carstens, Russ P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d University of Louisville   (United States)

^e UNIVERSITY OF LOUISVILLE   (United States)

^f NORTHWESTERN POLYTECHNICAL UNIVERSITY   (China)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN ESRP1; PROTEIN ESRP2; PROTEIN QKI; PROTEIN RBM47; REGULATOR PROTEIN; RNA BINDING PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ESRP1 PROTEIN, HUMAN; ESRP2 PROTEIN, HUMAN; QKI PROTEIN, HUMAN; RBM47 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; ARTICLE; BINDING SITE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE REGULATORY NETWORK; HUMAN; HUMAN CELL; IN VITRO STUDY; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; BIOLOGICAL MODEL; GENETICS; NEOPLASM; SEQUENCE ANALYSIS; TUMOR CELL LINE;

ALTERNATIVE SPLICING; CELL LINE, TUMOR; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE REGULATORY NETWORKS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RNA-BINDING PROTEINS; SEQUENCE ANALYSIS, RNA;

EID: 84971221634     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00019-16     Document Type: Article

References (72)

1. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. 2008. Deep surveying of alternative splicing complexity in the human transcriptome by highthroughput sequencing. Nat Genet 40:1413-1415. http://dx.doi.org/10.1038/ng.259.
2. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. 2008. Alternative isoform regulation in human tissue transcriptomes. Nature 456:470-476. http://dx.doi.org/10.1038/nature07509.
3. Moroy T, Heyd F. 2007. The impact of alternative splicing in vivo: mouse models show the way. RNA 13:1155-1171. http://dx.doi.org/10.1261/rna.554607.
4. Nilsen TW, Graveley BR. 2010. Expansion of the eukaryotic proteome by alternative splicing. Nature 463:457-463. http://dx.doi.org/10.1038/nature08909.
5. Lee KY, Li M, Manchanda M, Batra R, Charizanis K, Mohan A, Warren SA, Chamberlain CM, Finn D, Hong H, Ashraf H, Kasahara H, Ranum LP, Swanson MS. 2013. Compound loss of muscleblind-like function in myotonic dystrophy. EMBO Mol Med 5:1887-1900. http://dx.doi.org/10.1002/emmm.201303275.
6. Licatalosi DD, Yano M, Fak JJ, Mele A, Grabinski SE, Zhang C, Darnell RB. 2012. Ptbp2 represses adult-specific splicing to regulate the generation of neuronal precursors in the embryonic brain. Genes Dev 26:1626-1642. http://dx.doi.org/10.1101/gad.191338.112.
7. Li Q, Zheng S, Han A, Lin C-H, Stoilov P, Fu X-D, Black DL. 2014. The splicing regulator PTBP2 controls a program of embryonic splicing required for neuronal maturation. Elife 3:e01201. http://dx.doi.org/10.7554/eLife.01201.
8. Ule J, Jensen KB, Ruggiu M, Mele A, Ule A, Darnell RB. 2003. CLIP identifies Nova-regulated RNA networks in the brain. Science 302:1212-1215. http://dx.doi.org/10.1126/science.1090095.
9. Gehman LT, Meera P, Stoilov P, Shiue L, O'Brien JE, Meisler MH, Ares M, Otis TS, Black DL. 2012. The splicing regulator Rbfox2 is required for both cerebellar development and mature motor function. Genes Dev 26: 445-460. http://dx.doi.org/10.1101/gad.182477.111.
10. Barash Y, Calarco JA, Gao W, Pan Q, Wang X, Shai O, Blencowe BJ, Frey BJ. 2010. Deciphering the splicing code. Nature 465:53-59. http://dx.doi.org/10.1038/nature09000.
11. Lamouille S, Xu J, Derynck R. 2014. Molecular mechanisms of epithelialmesenchymal transition. Nat Rev Mol Cell Biol 15:178-196. http://dx.doi.org/10.1038/nrm3758.
12. Lim J, Thiery JP. 2012. Epithelial-mesenchymal transitions: insights from development. Development 139:3471-3486. http://dx.doi.org/10.1242/dev.071209.
13. Nieto MA, Cano A. 2012. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol 22:361-368. http://dx.doi.org/10.1016/j.semcancer.2012.05.003.
14. Scheel C, Weinberg RA. 2012. Cancer stem cells and epithelialmesenchymal transition: concepts and molecular links. Semin Cancer Biol 22:396-403. http://dx.doi.org/10.1016/j.semcancer.2012.04.001.
15. Tiwari N, Gheldof A, Tatari M, Christofori G. 2012. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22:194-207. http://dx.doi.org/10.1016/j.semcancer.2012.02.013.
16. Singh A, Settleman J. 2010. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741-4751. http://dx.doi.org/10.1038/onc.2010.215.
17. Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM, Haley JD. 2011. A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis 28:137-155. http://dx.doi.org/10.1007/s10585-010-9367-3.
18. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA. 2010. Core epithelialto-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 107:15449-15454. http://dx.doi.org/10.1073/pnas.1004900107.
19. Warzecha CC, Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S, Guo W, Xing Y, Carstens RP. 2010. An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J 29: 3286-3300. http://dx.doi.org/10.1038/emboj.2010.195.
20. Warzecha CC, Shen S, Xing Y, Carstens RP. 2009. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol 6:546-562. http://dx.doi.org/10.4161/rna.6.5.9606.
21. Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH, Burge CB, Gertler FB. 2011. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 7:e1002218. http://dx.doi.org/10.1371/journal.pgen.1002218.
22. Horiguchi K, Sakamoto K, Koinuma D, Semba K, Inoue A, Inoue S, Fujii H, Yamaguchi A, Miyazawa K, Miyazono K, Saitoh M. 2012. TGF-beta drives epithelial-mesenchymal transition through deltaEF1-mediated downregulation of ESRP. Oncogene 31:3190-3201. http://dx.doi.org/10.1038/onc.2011.493.
23. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. 2008. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68:3645-3654. http://dx.doi.org/10.1158/0008-5472.CAN-07-2938.
24. Braeutigam C, Rago L, Rolke A, Waldmeier L, Christofori G, Winter J. 2014. The RNA-binding protein Rbfox2: an essential regulator of EMTdriven alternative splicing and a mediator of cellular invasion. Oncogene 33:1082-1092. http://dx.doi.org/10.1038/onc.2013.50.
25. Venables JP, Brosseau J-P, Gadea G, Klinck R, Prinos P, Beaulieu J-F, Lapointe E, Durand M, Thibault P, Tremblay K, Rousset F, Tazi J, Abou Elela S, Chabot B. 2013. RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues. Mol Cell Biol 33:396-405. http://dx.doi.org/10.1128/MCB.01174-12.
26. Lapuk A, Marr H, Jakkula L, Pedro H, Bhattacharya S, Purdom E, Hu Z, Simpson K, Pachter L, Durinck S, Wang N, Parvin B, Fontenay G, Speed T, Garbe J, Stampfer M, Bayandorian H, Dorton S, Clark TA, Schweitzer A, Wyrobek A, Feiler H, Spellman P, Conboy J, Gray JW. 2010. Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol Cancer Res 8:961-974. http://dx.doi.org/10.1158/1541-7786.MCR-09-0528.
27. Dittmar KA, Jiang P, Park JW, Amirikian K, Wan J, Shen S, Xing Y, Carstens RP. 2012. Genome-wide determination of a broad ESRPregulated posttranscriptional network by high-throughput sequencing. Mol Cell Biol 32:1468-1482. http://dx.doi.org/10.1128/MCB.06536-11.
28. Park SM, Gaur AB, Lengyel E, Peter ME. 2008. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the Ecadherin repressors ZEB1 and ZEB2. Genes Dev 22:894-907. http://dx.doi.org/10.1101/gad.1640608.
29. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. 2008. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593-601. http://dx.doi.org/10.1038/ncb1722.
30. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. 2009. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 33:591-601. http://dx.doi.org/10.1016/j.molcel.2009.01.025.
31. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. 2010. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28:511-515. http://dx.doi.org/10.1038/nbt.1621.
32. Shen S, Park JW, Lu ZX, Lin L, Henry MD, Wu YN, Zhou Q, Xing Y. 2014. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc Natl Acad Sci U S A 111: E5593-E5601. http://dx.doi.org/10.1073/pnas.1419161111.
33. Bebee TW, Park JW, Sheridan KI, Warzecha CC, Cieply BW, Rohacek AM, Xing Y, Carstens RP. 2015. The splicing regulators Esrp1 and Esrp2 direct an epithelial splicing program essential for mammalian development. eLife 4:e08954. http://dx.doi.org/10.7554/eLife.08954.
34. Ray D, Kazan H, Cook KB, Weirauch MT, Najafabadi HS, Li X, Gueroussov S, Albu M, Zheng H, Yang A, Na H, Irimia M, Matzat LH, Dale RK, Smith SA, Yarosh CA, Kelly SM, Nabet B, Mecenas D, Li W, Laishram RS, Qiao M, Lipshitz HD, Piano F, Corbett AH, Carstens RP, Frey BJ, Anderson RA, Lynch KW, Penalva LO, Lei EP, Fraser AG, Blencowe BJ, Morris QD, Hughes TR. 2013. A compendium of RNAbinding motifs for decoding gene regulation. Nature 499:172-177. http://dx.doi.org/10.1038/nature12311.
35. Anderson ES, Lin CH, Xiao X, Stoilov P, Burge CB, Black DL. 2012. The cardiotonic steroid digitoxin regulates alternative splicing through depletion of the splicing factors SRSF3 and TRA2B. RNA 18:1041-1049. http://dx.doi.org/10.1261/rna.032912.112.
36. Vanharanta S, Marney CB, Shu W, Valiente M, Zou Y, Mele A, Darnell RB, Massague J. 2014. Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer. eLife 3:e02734. http://dx.doi.org/10.7554/eLife.02734.
37. Pan Q, Shai O, Misquitta C, Zhang W, Saltzman AL, Mohammad N, Babak T, Siu H, Hughes TR, Morris QD, Frey BJ, Blencowe BJ. 2004. Revealing global regulatory features of mammalian alternative splicing using a quantitative microarray platform. Mol Cell 16:929-941. http://dx.doi.org/10.1016/j.molcel.2004.12.004.
38. Huang da W, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44-57. http://dx.doi.org/10.1038/nprot.2008.211.
39. Xu Y, Gao XD, Lee JH, Huang H, Tan H, Ahn J, Reinke LM, Peter ME, Feng Y, Gius D, Siziopikou KP, Peng J, Xiao X, Cheng C. 2014. Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing. Genes Dev 28:1191-1203. http://dx.doi.org/10.1101/gad.241968.114.
40. Fossat N, Tourle K, Radziewic T, Barratt K, Liebhold D, Studdert JB, Power M, Jones V, Loebel DA, Tam PP. 2014. C to U RNA editing mediated by APOBEC1 requires RNA-binding protein RBM47. EMBO Rep 15:903-910. http://dx.doi.org/10.15252/embr.201438450.
41. Licatalosi DD, Mele A, Fak JJ, Ule J, Kayikci M, Chi SW, Clark TA, Schweitzer AC, Blume JE, Wang X, Darnell JC, Darnell RB. 2008. HITS-CLIP yields genome-wide insights into brain alternative RNA processing. Nature 456:464-469. http://dx.doi.org/10.1038/nature07488.
42. Zhang C, Zhang Z, Castle J, Sun S, Johnson J, Krainer AR, Zhang MQ. 2008. Defining the regulatory network of the tissue-specific splicing factors Fox-1 and Fox-2. Genes Dev 22:2550-2563. http://dx.doi.org/10.1101/gad.1703108.
43. Hall MP, Nagel RJ, Fagg WS, Shiue L, Cline MS, Perriman RJ, Donohue JP, Ares M, Jr. 2013. Quaking and PTB control overlapping splicing regulatory networks during muscle cell differentiation. RNA 19:627-638. http://dx.doi.org/10.1261/rna.038422.113.
44. Wu JI, Reed RB, Grabowski PJ, Artzt K. 2002. Function of quaking in myelination: regulation of alternative splicing. Proc Natl Acad Sci U S A 99:4233-4238. http://dx.doi.org/10.1073/pnas.072090399.
45. Larocque D, Pilotte J, Chen T, Cloutier F, Massie B, Pedraza L, Couture R, Lasko P, Almazan G, Richard S. 2002. Nuclear retention of MBP mRNAsin the quaking viable mice. Neuron 36:815-829. http://dx.doi.org/10.1016/S0896-6273(02)01055-3.
46. Li Z, Zhang Y, Li D, Feng Y. 2000. Destabilization and mislocalization of myelin basic protein mRNAs in quaking dysmyelination lacking the QKI RNA-binding proteins. J Neurosci 20:4944-4953.
47. Chen AJ, Paik JH, Zhang H, Shukla SA, Mortensen R, Hu J, Ying H, Hu B, Hurt J, Farny N, Dong C, Xiao Y, Wang YA, Silver PA, Chin L, Vasudevan S, Depinho RA. 2012. STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. Genes Dev 26: 1459-1472. http://dx.doi.org/10.1101/gad.189001.112.
48. Zhao L, Mandler MD, Yi H, Feng Y. 2010. Quaking I controls a unique cytoplasmic pathway that regulates alternative splicing of myelinassociated glycoprotein. Proc Natl Acad Sci U S A 107:19061-19066. http://dx.doi.org/10.1073/pnas.1007487107.
49. Saccomanno L, Loushin C, Jan E, Punkay E, Artzt K, Goodwin EB. 1999. The STAR protein QKI-6 is a translational repressor. Proc Natl Acad Sci U S A 96:12605-12610. http://dx.doi.org/10.1073/pnas.96.22.12605.
50. Zhao L, Ku L, Chen Y, Xia M, LoPresti P, Feng Y. 2006. QKI binds MAP1B mRNA and enhances MAP1B expression during oligodendrocyte development. Mol Biol Cell 17:4179-4186. http://dx.doi.org/10.1091/mbc.E06-04-0355.
51. Bockbrader K, Feng Y. 2008. Essential function, sophisticated regulation and pathological impact of the selective RNA-binding protein QKI in CNS myelin development. Future Neurol 3:655-668. http://dx.doi.org/10.2217/14796708.3.6.655.
52. Ebersole TA, Chen Q, Justice MJ, Artzt K. 1996. The quaking gene product necessary in embryogenesis and myelination combines features of RNA binding and signal transduction proteins. Nat Genet 12:260-265. http://dx.doi.org/10.1038/ng0396-260.
53. Zong FY, Fu X, Wei WJ, Luo YG, Heiner M, Cao LJ, Fang Z, Fang R, Lu D, Ji H, Hui J. 2014. The RNA-binding protein QKI suppresses cancer-associated aberrant splicing. PLoS Genet 10:e1004289. http://dx.doi.org/10.1371/journal.pgen.1004289.
54. Galarneau A, Richard S. 2005. Target RNA motif and target mRNAs of the Quaking STAR protein. Nat Struct Mol Biol 12:691-698. http://dx.doi.org/10.1038/nsmb963.
55. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano M, Jr, Jungkamp AC, Munschauer M, Ulrich A, Wardle GS, Dewell S, Zavolan M, Tuschl T. 2010. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 141:129-141. http://dx.doi.org/10.1016/j.cell.2010.03.009.
56. Ryder SP, Williamson JR. 2004. Specificity of the STAR/GSG domain protein Qk1: implications for the regulation of myelination. RNA 10: 1449-1458. http://dx.doi.org/10.1261/rna.7780504.
57. Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, Roslan S, Schreiber AW, Gregory PA, Goodall GJ. 2015. The RNA binding protein quaking regulates formation of circRNAs. Cell 160:1125-1134. http://dx.doi.org/10.1016/j.cell.2015.02.014.
58. Lu HZ, Liu JL, Liu SJ, Zeng JW, Ding DQ, Carstens RP, Cong YS, Xu XW, Guo W. 2013. Exo70 isoform switching upon epithelialmesenchymal transition mediates cancer cell invasion. Dev Cell 27:560-573. http://dx.doi.org/10.1016/j.devcel.2013.10.020.
59. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, Cheng CH. 2011. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 121:1064-1074. http://dx.doi.org/10.1172/JCI44540.
60. Gardner K, Bennett V. 1987. Modulation of spectrin-actin assembly by erythrocyte adducin. Nature 328:359-362. http://dx.doi.org/10.1038/328359a0.
61. Kaiser HW, O'Keefe E, Bennett V. 1989. Adducin: Ca++-dependent association with sites of cell-cell contact. J Cell Biol 109:557-569. http://dx.doi.org/10.1083/jcb.109.2.557.
62. Naydenov NG, Ivanov AI. 2010. Adducins regulate remodeling of apical junctions in human epithelial cells. Mol Biol Cell 21:3506-3517. http://dx.doi.org/10.1091/mbc.E10-03-0259.
63. Rotzer V, Breit A, Waschke J, Spindler V. 2014. Adducin is required for desmosomal cohesion in keratinocytes. J Biol Chem 289:14925-14940. http://dx.doi.org/10.1074/jbc.M113.527127.
64. Matsuoka Y, Li X, Bennett V. 1998. Adducin is an in vivo substrate for protein kinase C: phosphorylation in the MARCKS-related domain inhibits activity in promoting spectrin-actin complexes and occurs in many cells, including dendritic spines of neurons. J Cell Biol 142:485-497. http://dx.doi.org/10.1083/jcb.142.2.485.
65. Huttlin EL, Jedrychowski MP, Elias JE, Goswami T, Rad R, Beausoleil SA, Villén J, Haas W, Sowa ME, Gygi SP. 2010. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143:1174-1189. http://dx.doi.org/10.1016/j.cell.2010.12.001.
66. Lundby A, Secher A, Lage K, Nordsborg NB, Dmytriyev A, Lundby C, Olsen JV. 2012. Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3:876. http://dx.doi.org/10.1038/ncomms1871.
67. Barnett TR, Kretschmer A, Austen DA, Goebel SJ, Hart JT, Elting JJ, Kamarck ME. 1989. Carcinoembryonic antigens-alternative splicing accounts for the multiple messenger-RNAs that code for novel members of the carcinoembryonic antigen family. J Cell Biol 108:267-276. http://dx.doi.org/10.1083/jcb.108.2.267.
68. Dráberová L, Černá H, Brodská H, Boubelík M, Watt SM, Stanners CP, Dráber P. 2000. Soluble isoforms of CEACAM1 containing the A2 domain: increased serum levels in patients with obstructive jaundice and differences in 3-fucosyl-N-acetyl-lactosamine moiety. Immunology 101: 279-287. http://dx.doi.org/10.1046/j.1365-2567.2000.00113.x.
69. Sundberg U, Obrink B. 2002. CEACAM1 isoforms with different cytoplasmic domains show different localization, organization and adhesive properties in polarized epithelial cells. J Cell Sci 115(Pt 6):1273-1284.
70. Huber M, Izzi L, Grondin P, Houde C, Kunath T, Veillette A, Beauchemin N. 1999. The carboxyl-terminal region of biliary glycoprotein controls its tyrosine phosphorylation and association with proteintyrosine phosphatases SHP-1 and SHP-2 in epithelial cells. J Biol Chem 274:335-344. http://dx.doi.org/10.1074/jbc.274.1.335.
71. Gaur S, Shively J, Yen Y, Gaur R. 2008. Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms. Mol Cancer 7:46. http://dx.doi.org/10.1186/1476-4598-7-46.
72. Yang J, Weinberg RA. 2008. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14:818-829. http://dx.doi.org/10.1016/j.devcel.2008.05.009.